ScholarIQanswers from OpenAlex & ORCID
Randy D. Gascoyne
ResearcherPublications, citations & collaboration network
Randy D. Gascoyne is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Randy D. Gascoyne have?
ScholarIQindexed works
Randy D. Gascoyne has 1,004 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Randy D. Gascoyne have?
ScholarIQcitation count
Randy D. Gascoyne has 108,387 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Randy D. Gascoyne?
ScholarIQh-index
Randy D. Gascoyne has an h-index of 153 in OpenAlex.
What is the i10-index of Randy D. Gascoyne?
ScholarIQi10-index
Randy D. Gascoyne has an i10-index of 498 in OpenAlex.
What is the ORCID of Randy D. Gascoyne?
ScholarIQorcid
The ORCID for Randy D. Gascoyne is on the source record.
What is the OpenAlex record for Randy D. Gascoyne?
ScholarIQopenalex
The OpenAlex for Randy D. Gascoyne is on the source record.
What are the most-cited papers on Randy D. Gascoyne?
ScholarIQmost cited works
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin, Nathalie A. Johnson, Tesa Severson, Andrew J. Mungall, Jianghong An, Rodrigo Goya, Jessica E. Paul, Merrill Boyle, Bruce W. Woolcock, Florian Kuchenbauer, Damian Yap, R. Keith Humphries, Obi L. Griffith, Sohrab P. Shah, Henry Zhu, Michelle Kimbara, Pavel Shashkin, Jean Charlot, Marianna Tcherpakov, Richard Corbett, Angela Tam, Richard Varhol, Duane E. Smailus, Michelle Moksa, Yongjun Zhao, Allen Delaney, Hong Qian, İnanç Birol, Jacqueline E. Schein, Richard A. Moore, Robert A. Holt, Doug Horsman, Joseph M. Connors, Steven J.M. Jones, Samuel Aparício, Martin Hirst, Randy D. Gascoyne, Marco A. Marra
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann, Edie Weller, Vicki A. Morrison, Randy D. Gascoyne, Peter A. Cassileth, Jeffrey Cohn, Shaker R. Dakhil, Bruce A. Woda, Richard I. Fisher, B. A. Peterson, Sandra J. Horning
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl, Tang Lee, Sohrab P. Shah, Pedro Farinha, Guangming Han, Tarun Nayar, Allen Delaney, Steven J.M. Jones, Javeed Iqbal, Dennis D. Weisenburger, Martin Bast, Andreas Rosenwald, Hans-Konrad Müller-Hermelink, Lisa M. Rimsza, Elı́as Campo, Jan Delabie, Rita M. Braziel, James R. Cook, R. Tubbs, Elaine S. Jaffe, Georg Lenz, Joseph M. Connors, Louis M. Staudt, Wing C. Chan, Randy D. Gascoyne
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, Carlo Visco, Yong Li, Roberto N. Miranda, Santiago Montes‐Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, Xiaoying Zhao, J. Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Z. Ai, Maurilio Ponzoni, Andrés J.M. Ferreri, Fan Zhou, Graham W. Slack, Randy D. Gascoyne, Meifeng Tu, Daina Variakojis, Weina Chen, Ronald S. Go, Miguel Á. Piris, Michael Møller, L. Jeffrey Medeiros, Ken H. Young